{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:24:15Z","timestamp":1794349455560,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eclinm.2025.103645","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:25:35Z","timestamp":1763504735000},"page":"103645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Reza","family":"Eshraghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-7098","authenticated-orcid":false,"given":"Delaram J.","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Montazerinamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2158-2567","authenticated-orcid":false,"given":"Ashkan","family":"Bahrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1605-2848","authenticated-orcid":false,"given":"Yash","family":"Kachela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Rezasoltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Namazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-7263","authenticated-orcid":false,"given":"Mohsan","family":"Subhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3694-6863","authenticated-orcid":false,"given":"Pouya","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eclinm.2025.103645_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000072222","article-title":"Alcohol as a risk factor for global burden of disease","volume":"9","author":"Rehm","year":"2003","journal-title":"Eur Addict Res"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103645_bib2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1360-0443.2003.00467.x","article-title":"The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview","volume":"98","author":"Rehm","year":"2003","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-pharmtox-031323-115847","article-title":"Alcohol use disorder treatment: problems and solutions","volume":"64","author":"Koob","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103645_bib4","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103645_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103645_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMct0801733","article-title":"Naltrexone for the management of alcohol dependence","volume":"359","author":"Anton","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103645_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102920","article-title":"Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review","volume":"78","author":"Subhani","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103645_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103645_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review \u2013 glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns","year":"2024","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103645_bib10","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103645_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103645_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146562","article-title":"Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1","volume":"1727","author":"Jerlhag","year":"2020","journal-title":"Brain Res"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103645_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1369-1600.2012.00464.x","article-title":"Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review","volume":"18","author":"Schacht","year":"2013","journal-title":"Addict Biol"},{"key":"10.1016\/j.eclinm.2025.103645_bib15","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103645_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1080\/00952990.2018.1456545","article-title":"A review of the alcohol use disorders identification test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: past issues and future directions","volume":"44","author":"Higgins-Biddle","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.eclinm.2025.103645_bib17","series-title":"Diagnostic and statistical manual of mental disorders. Diagnostic and statistical manual of mental disorders","year":"2013"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103645_bib18","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/dom.16152","article-title":"Glucagon-like peptide-1 analogues reduce alcohol intake","volume":"27","author":"O'Farrell","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib20","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103645_bib21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103645_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib24","first-page":"1","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103645_bib25","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/apt.70007","article-title":"Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103645_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eclinm.2025.103645_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/acer.70041","article-title":"Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption","author":"Jensen","year":"2025","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.eclinm.2025.103645_bib28","article-title":"Association of GLP-1 receptor agonists with liver-related outcomes and all-cause mortality in patients with harmful alcohol use: a target trial emulation study","author":"John","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"22","key":"10.1016\/j.eclinm.2025.103645_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.eclinm.2025.103645_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.eclinm.2025.103645_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2020.614884","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2021","journal-title":"Front Behav Neurosci"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuint.2013.10.003","article-title":"Moving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug reward","volume":"73","author":"Reddy","year":"2014","journal-title":"Neurochem Int"},{"issue":"7 OCT","key":"10.1016\/j.eclinm.2025.103645_bib33","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front Neurosci"},{"key":"10.1016\/j.eclinm.2025.103645_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35716-1","article-title":"Revealing the tissue-level complexity of endogenous glucagon-like peptide-1 receptor expression and signaling","volume":"14","author":"Ast","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2025.103645_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110303","article-title":"The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review","volume":"110","author":"Guerrero-Hreins","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103645_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.physbeh.2013.04.003","article-title":"Role of central glucagon-like peptide-1 in stress regulation","volume":"122","author":"Ghosal","year":"2013","journal-title":"Physiol Behav"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103645_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/23312025.2016.1229086","article-title":"The physiological role of the brain GLP-1 system in stress","volume":"2","author":"Holt","year":"2016","journal-title":"Cogent Biol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:34:26Z","timestamp":1794346466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025005796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"alternative-id":["S2589537025005796"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103645","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103645"}}